Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib
Carcinoma, Renal Cell
Protein Kinase Inhibitors
Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post-first-dose axitinib plasma concentrations within a specific range.